CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  2014 Report on the Japanese Hepatitis C Virus - Drug Forecast and Market Analysis to 2022

[January 21, 2014]

2014 Report on the Japanese Hepatitis C Virus - Drug Forecast and Market Analysis to 2022

(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/p46jh2/pharmapoint) has announced the addition of the "2014 Report on the Japanese Hepatitis C Virus - Drug Forecast and Market Analysis to 2022" report to their offering.

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection.

Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The current standard of HCV therapy in Japan is a combination of interferon and ribavirin. The less-frequent dosing of peginterferon compared with standard interferon (i.e., once a week compared with three times a week) enabled peginterferon to quickly capture market share. In addition to standard interferon, PegIntron directly competes for market share with Roche's Pegasys (peginterferon alfa-2a). Our primary research revealed that peginterferon market position is further bolstered by the frequent use of interferon monotherapy in Japan.

Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/p46jh2/pharmapoint CONTACT: Research and Markets, Laura Wood, Senior Manager.

press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Infectious Diseases (http://www.researchandmarkets.com/categories.asp?cat_id=121&campaign_id=p46jh2) .

(c) 2014 M2 COMMUNICATIONS

[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter